Minnesota-based St. Jude Medical (NYSE: STJ) announced Wednesday that the Food & Drug Administration has approved a new pericardial aortic stented tissue valve -- the Trifecta. In a statement ...

ST. PAUL, Minn., St. Jude Medical, Inc., a global medical device company, today announced the first human implant of its Portico(TM) transcatheter aortic heart valve. The procedure was performed by Dr ...

“will help us provide the best care possible for our patients in need of aortic valve replacement and especially those with challenging clinical cases.” The new Trifecta GT valve builds on St. Jude ...

St. Jude Medical today announced the U.S. launch of the Trifecta™ valve with Glide™ Technology for the treatment of patients diagnosed with unhealthy, ...

St. Jude said. "The promise of the Trifecta tissue valve to potentially deliver superior hemodynamic performance to currently available stented or stentless aortic valves is very exciting," said ...

The Portico device is the only approved transcatheter valve that can ... with diseased or damaged aortic heart valves," said Frank J. Callaghan, president of the St. Jude Medical Cardiovascular ...

Medical device manufacturer, St. Jude Medical, Inc.STJ recently announced the receipt of CE Mark approval for its 27mm and 29mm Portico Transcatheter Aortic Valve Replacement (TAVR) Systems.

--(BUSINESS WIRE)-- St. Jude Medical, Inc. (NYS: STJ) , a global medical device company, today announced the first patient implant of its 23 mm Portico™ Transcatheter Aortic Heart Valve using ...